https://scholars.lib.ntu.edu.tw/handle/123456789/512575
標題: | The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy | 作者: | Omori Y. Enatsu S. Brnabic A.J.M. Rajan N. JIN-YUAN SHIH Kim J.-H. Park K. Inoue A. |
關鍵字: | Docetaxel; Febrile neutropenia; Non-small cell lung cancer; Patient-reported outcome; Quality of life | 公開日期: | 2019 | 出版社: | Japan Lung Cancer Society | 卷: | 59 | 期: | 7 | 起(迄)頁: | 1140-1150 | 來源出版物: | Japanese Journal of Lung Cancer | 摘要: | Objectives. The relevance of febrile neutropenia (FN) to patient-reported outcomes (PROs) was examined in Japanese, East Asian (EA), and non-EA patients with stage IV non-small cell lung cancer. Materials and Methods. PROs were assessed with the Lung Cancer Symptom Scale (LCSS) and EuroQoL-5 Dimensions (EQ-5D) at baseline, every cycle, at discontinuation, and at 30-day follow-up. The time to deterioration (TtD) and mean changes (baseline to treatment completion) in the LCSS total score, average symptom burden index (ASBI), and EQ-5 D visual analog scale (VAS) scores were analyzed by the FN status, regardless of the assigned treatment. Results. For patients with and without FN, the hazard ratios (HRs; 95% confidence interval [CI]) for TtD of the LCSS total, ASBI, and EQ-5D VAS scores were 0.731 (0.469-1.141), 0.621 (0.399-0.967), and 0.802 (0.537-1.199) in Japanese patients, and 0.572 (0.250-1.313), 0.506 (0.228-1.121), and 0.792 (0.350-1.790) in EA patients, respectively, indicating a longer TtD in PROs for patients without FN than for those with FN, while no marked differences by the FN status were noted in non-EA patients. Across the three populations, the mean change in both the LCSS total and EQ-5D VAS scores demonstrated a greater deterioration at treatment completion for patients with FN than for those without FN. Conclusions. PROs deteriorated more rapidly in patients with FN than in those without FN among Japanese and EA patients but not non-EA patients. Upon treatment completion, PROs were better maintained in patients without FN than in those with FN in all three populations. These findings suggest that active prevention of FN may help maintain PROs during treatment, regardless of ethnic group (ClinicalTrials.gov registration: NCT 01703091 and NCT01168973). ? 2019 The Japan Lung Cancer Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077860062&doi=10.2482%2fhaigan.59.1140&partnerID=40&md5=01bc6cd526fd0853d3cb3200ebce548c https://scholars.lib.ntu.edu.tw/handle/123456789/512575 |
ISSN: | 0386-9628 | DOI: | 10.2482/haigan.59.1140 | SDG/關鍵字: | angiogenesis inhibitor; docetaxel; advanced cancer; antiangiogenic therapy; Article; cancer combination chemotherapy; cancer staging; controlled study; febrile neutropenia; follow up; human; non small cell lung cancer; post hoc analysis; quality of life; randomized controlled trial (topic); symptom; visual analog scale |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。